Solid organ transplant recipients are more than twice as likely to die from cancer compared to the general population, according to a large UK study. Non-Hodgkin lymphoma carried the highest mortality risk, while cancers like prostate, thyroid, and breast showed no increased risk. The findings highlight the need for long-term cancer monitoring in transplant patients.
A large population-based study out of England found that solid organ transplant (SOT) recipients face significantly elevated cancer-related mortality compared to the general population. Analyzing over 50,000 transplant recipients across nearly three decades, researchers found that cancer deaths occurred at more than double the expected rate — translating to 29 extra deaths per 10,000 person-years.
The risk wasn't uniform across cancer types. Non-Hodgkin lymphoma — often linked to posttransplant lymphoproliferative disorder (PTLD) — showed the starkest elevation, while organ-specific cancers like liver cancer in liver recipients and kidney cancer in kidney recipients were also markedly higher. Interestingly, South Asian, Black, and Chinese or East Asian recipients had notably lower cancer mortality risk than White recipients.
By the Numbers:
Why it matters: Transplant recipients are on long-term immunosuppression, which blunts the immune system's ability to fight off cancer. This study reinforces the urgent need for tailored, long-term cancer surveillance protocols — especially for PTLD — in transplant care programs.
